Movalis (Meloxicam)

Meloxicam works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for converting arachidonic acid into prostaglandins that promote inflammation, pain, and fever. By blocking COX‑2 more than COX‑1, meloxicam decreases prostaglandin production at sites of inflammation while preserving protective gastric prostaglandins, resulting in anti‑inflammatory and analgesic effects.

The dosage of Movalis is determined by the prescribing clinician based on the patient’s condition, severity of pain, and individual health factors. The healthcare provider selects the appropriate amount and frequency of the intramuscular injection, and patients should follow the prescribed regimen without alteration.

The safety of meloxicam in pregnancy and lactation has not been established, and it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Movalis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher selectivity for COX‑2, which may reduce the incidence of gastrointestinal side effects while still providing effective anti‑inflammatory and analgesic action. However, it shares similar cardiovascular and renal risk profiles with other NSAIDs, and the choice of therapy depends on individual patient risk factors and clinical judgment.

Movalis for intramuscular injection should be stored at controlled room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before administration, inspect the vial for particulate matter or discoloration and follow aseptic techniques as recommended in the product’s prescribing information.

Movalis is supplied as a sterile solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, using aseptic technique. The injection site should be rotated as appropriate, and the patient should be observed for any immediate adverse reactions following administration.

The most serious risks include gastrointestinal ulceration or bleeding, severe allergic reactions such as anaphylaxis, liver injury, renal impairment, and cardiovascular events like myocardial infarction or stroke. Patients with a history of ulcer disease, heart failure, kidney disease, or those taking anticoagulants should be monitored closely, and any signs of serious adverse effects require immediate medical attention.

Movalis should not be used in patients with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, or in the third trimester of pregnancy. It is also contraindicated in individuals receiving certain anticoagulants or those with a history of cardiovascular events unless the prescribing physician determines that the benefits outweigh the risks.